Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + pamabrom
- Development stage
- Approved
- Lead developer
- Lepu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ibuprofen + pamabrom is a fixed-dose combination small molecule drug developed by Lepu Pharmaceutical and marketed under the brand name Aijia (艾佳). It is approved in China for the relief of symptoms associated with the menstrual cycle, including dysmenorrhea, breast tenderness, headache, edema, and irritability. The combination consists of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to provide analgesic and anti-inflammatory effects, and pamabrom, a mild diuretic (8-bromotheophylline derivative) that reduces water retention and bloating.
- Brand names
- 艾佳Aijia
- Other names
- ibuprofen bromideIbuprofen and Pamabrom布洛芬帕马溴
02
Targets
ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADOR (Adenosine receptors)
Beyond the preview
Go deeper on ibuprofen + pamabrom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + pamabrom.